

Title (en)
THERAPEUTIC USE OF AZIRIDINO COMPOUNDS

Title (de)
THERAPEUTISCHE VERWENDUNG VON AZIRIDINOVERBINDUNGEN

Title (fr)
UTILISATION THERAPEUTIQUE DE COMPOSES AZIRIDINO

Publication
EP 1451308 A4 20041117 (EN)

Application
EP 02806003 A 20021105

Priority
• US 0235501 W 20021105
• US 0149956 W 20011106
• US 36564802 P 20020318
• US 37918802 P 20020509

Abstract (en)
[origin: WO03066806A2] Methods are provided for treatment of diseases. The methods include preventing or inhibiting transcription and/or replication of a nucleic acid molecule by administering to a subject in need of such treatment an effective amount of one or more aziridino compounds. Pharmaceutical compositions comprising the one or more aziridino compounds also are provided.

IPC 1-7
A61K 35/14; A61K 31/395; A61P 37/00; A61P 35/00

IPC 8 full level
C07D 203/12 (2006.01); **A61K 9/19** (2006.01); **A61K 9/20** (2006.01); **A61K 9/28** (2006.01); **A61K 9/48** (2006.01); **A61K 9/52** (2006.01); **A61K 31/396** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61P 1/04** (2006.01); **A61P 1/16** (2006.01); **A61P 3/10** (2006.01); **A61P 7/04** (2006.01); **A61P 7/06** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 19/04** (2006.01); **A61P 21/00** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 31/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/10** (2006.01); **A61P 31/12** (2006.01); **A61P 33/02** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/06** (2006.01); **A61P 37/08** (2006.01)

CPC (source: EP)
A61K 31/396 (2013.01); **A61K 45/06** (2013.01); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 3/10** (2017.12); **A61P 7/04** (2017.12); **A61P 7/06** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 19/04** (2017.12); **A61P 21/00** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 31/00** (2017.12); **A61P 31/04** (2017.12); **A61P 31/10** (2017.12); **A61P 31/12** (2017.12); **A61P 33/02** (2017.12); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **A61P 37/06** (2017.12); **A61P 37/08** (2017.12); **Y02A 50/30** (2017.12)

Citation (search report)
• [XA] EP 0419890 A2 19910403 - AMERICAN CYANAMID CO [US]
• [Y] WO 9707674 A1 19970306 - PENTOSE PHARMACEUTICALS INC [US], et al
• [PA] WO 02055095 A2 20020718 - VI TECHNOLOGIES INC [US], et al
• [X] FAST-L: "Treatment of human leukocytes with inactine-TM results in loss of function and induction of apoptosis", BLOOD, vol. 96, no. 11, 16 November 2000 (2000-11-16), pages 61A, XP001073993
• [X] KASERMANN FABIAN ET AL: "Virus inactivation and protein modifications by ethyleneimines", ANTIVIRAL RESEARCH, vol. 52, no. 1, October 2001 (2001-10-01), pages 33 - 41, XP002296019, ISSN: 0166-3542
• [PX] PURMAL ANDREI ET AL: "Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: Preclinical studies", TRANSFUSION (BETHESDA), vol. 42, no. 2, February 2002 (2002-02-01), pages 139 - 145, XP002296020, ISSN: 0041-1132
• [Y] RICHTER H I ET AL: "[Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus]", DER HAUTARZT;ZEITSCHRIFT FUR DERMATOLOGIE, VENEROLOGIE, UND VERWANDTE GEBIETE. GERMANY JUN 1998, vol. 49, no. 6, June 1998 (1998-06-01), pages 487 - 491, XP002203620, ISSN: 0017-8470
• [Y] CHAPMAN JOHN: "Progress in improving the pathogen safety of red cell concentrates.", VOX SANGUINIS, vol. 78, no. Suppl. 2, July 2000 (2000-07-01), pages 203 - 204, XP008004989, ISSN: 0042-9007
• See references of WO 03066806A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)
WO 03066806 A2 20030814; WO 03066806 A3 20031224; AU 2002366446 A1 20030902; CA 2466251 A1 20030814; EP 1451308 A2 20040901; EP 1451308 A4 20041117; JP 2005517023 A 20050609

DOCDB simple family (application)
US 0235501 W 20021105; AU 2002366446 A 20021105; CA 2466251 A 20021105; EP 02806003 A 20021105; JP 2003566157 A 20021105